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Risk factorsThe presence of anti-phospholipid (aPL) is necessary but not sufﬁcient to induce a thrombotic event. The
“second hit” hypothesis suggested that an additional trigger may be needed to develop a vascular event in
aPL carriers. In this article, pro and con of primary thromboprophylaxis in aPL carriers is deeply discussed,
concluding that univocal data are not available, due to conﬂicting results of available clinical trials. However,
in clinical practice the primary thromboprophylaxis is not indicated in all unselected asymptomatic aPL car-
riers, and the best strategy begin with the assessment of the peculiar risk proﬁle of the subject. Thus, it is
mandatory to eliminate modiﬁable prothrombotic risk factors (i.e. smoking, oral contraceptive), to treat
the irreversible risk factors (i.e. hypertension, diabetes) and to introduce an aggressive prophylaxis with sub-
cutaneous LMWH in high-risk situations (i.e. surgical procedures with prolonged immobilization). A different
evaluation should be addressed to aPL carriers with a concomitant autoimmune disease that are considered
as an additional pro-thrombotic risk factor. Similarly, concomitant positivity for more than one anti-
phospholipid test confer a stronger risk of developing the thrombotic manifestations. Speciﬁc trials with larg-
er cohorts of patients are needed to better clarify this issue.
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Since its discovery, it has been clear that Anti-phospholipid Syndrome
(APS) is characterized by thrombosis; however, anti-phospholipid (aPL)
are necessary but not sufﬁcient to induce a thrombotic event. The “second
hit” hypothesis has been suggested to explain this apparent paradox: ansini).
sevier B.V.
Thromboprophylaxis in carri
11), doi:10.1016/j.autrev.20additional trigger may be needed to develop a vascular event in aPL car-
riers and up to a third of patients have other thrombotic risk factors at the
time of the event. It has been demonstrated that aPL positive patients
have a whole risk of thrombosis ranging between 0 and 3.8% [1]. In cer-
tain circumstances, primary thromboprophylaxis may be needed also in
aPL carriers without any previous thrombotic event. Difference in inci-
dence of thrombotic events between patients and asymptomatic carriers
with aPL depends at least partially on the proportion of coincident non-
aPL thrombotic risk factors [2]. The elimination of reversible thrombosis
risk factors (such as smoking or use of oral contraceptives) and the use ofers of antiphospholipid antibodies (APL) without previous thrombo-
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crucial.
A consensus document has been elaborated at the 13th International
Congress on Antiphospholipid Antibodies, held in Galveston in April
2010, on the primary and secondary thromboprophylaxis in individuals
with aPL, after a systematic and critical review of the literature [3].
When considering thromboprophylaxis in aPL positive subjects vari-
ables to take into account are aPL proﬁle (type, levels, persistence),
other associated risk factors and underlying autoimmune disease.
Thus, the presence of Lupus Anticoagulant (LA), particularly if combined
with anti-cardiolipin (aCL) and anti-β2-GPI (a-β2GPI) (the so called “tri-
ple positivity”), and the presence of isolated, persistently positive aCL at
medium–high levels is considered a high-risk serological aPL proﬁle.
Systemic autoimmune diseases such as Systemic Lupus Eryhte-
matosus (SLE) are now considered independent cardiovascular
risk factor and they have to be considered when evaluating prima-
ry thromboprophylaxis.
When approaching aPL positive patients, a balance between indi-
vidual risk of thrombosis and beneﬁts and risks induced by antith-
rombotic therapies is mandatory.
2. Thromboprophylaxis in aPL carriers without previous thrombosis:
“pro” view
APS is characterized by vascular thrombosis and/or fetal morbidi-
ty, in the presence of aPL. aPL are a heterogeneous group of antibodies
directed against phospholipid-binding proteins, currently detectable
by anti-cardiolipin (anti-CL), anti-β2 glycoprotein I (anti-β2GPI) and
lupus anticoagulanlt (LA) assays. aPL are not only diagnostic markers
of APS, but are also considered to exert a pathogenetic role. Experimental
data suggest aPL are necessary but not sufﬁcient to trigger a thrombotic
event: a “second hit”would be required to induce a vascular manifesta-
tion. Among the three assays, LA has been shown to best correlate with
the occurrence of both arterial and venous thromboses, while
anti-β2GPI and anti-CL are apparently less strongly associated. It has
been demonstrated that the concomitant positivity for more than one
test, particularly LA positivity, the IgG isotype and medium-high titers
confer a stronger risk of developing the clinical manifestations of the
syndrome. There is extensive evidence that patients with APS, being at
high-risk of recurrence of thrombotic events, beneﬁt from long-term
anticoagulation. Much more debated is the management of asymptom-
atic patients with aPL positivity conﬁrmed 12 weeks apart, without a
clinical history of venous or arterial thrombosis. To date, few clinical tri-
als have addressed the role of primary prophylaxis in asymptomatic aPL
subjects, and not univocal results have been reported [2,4–6]. Moreover,
the limited number of patients enrolled and the low incidence of out-
come events make even more difﬁcult to draw deﬁnitive conclusions.
In fact, aPL carriers present a rather low rate of vascular manifestations:
a 3-year prospective observational cohort-study on 178 asymptomatic
aPL carriers without underlying autoimmune diseases reported no
thrombotic events in those not receiving primary prophylaxis [2]. The
only randomized, double-blind, placebo-controlled trial (the APLASA
study) investigating the efﬁcacy of low-dose aspirin (LDA) as primary
prevention of thrombotic events suggested aPL-positive individuals do
not beneﬁt fromprimary thrombosis prophylaxis: among98 asymptom-
atic aPL carriers, LDA was not more effective than placebo for primary
prophylaxis of thrombotic events. aPL-positive individuals were found
to develop a ﬁrst vascular event when additional procoagulant risk fac-
tors were present [4]. Concordingly, retrospective cohort studies
reported that 46–76% of APS patients have other thrombotic risk factors
at the time of vascular events. Among these, conventional cardiovascular
risk factors as hypertension, diabetes, hypercholesterolemia, smoking
and obesity play a pivotal role [5,2,7–10]. In particular, an Italian collab-
orative study group prospectively identiﬁed hypertension and LA as inde-
pendent risk factors for a ﬁrst thrombotic event among asymptomatic aPL
carriers [11]. Inherited cause of thrombophilia must also be taken intoPlease cite this article as: Ceccarelli F, et al, Thromboprophylaxis in carri
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deﬁciency, homozygous mutation in methylenetetrahydrofolate reduc-
tase gene leading to plasmatic hyperhomocysteinemia. Puerperium, trau-
ma, infection, surgery and prolonged immobilization should also be
regarded as transient high-risk conditions for venous thrombosis.
There is a growing body of evidence showing that a propermanagement
of modiﬁable prothrombotic risk factors may abate the actual risk of a
major vascular event. Therefore, it is strongly advisable to promptly cor-
rect modiﬁable risk factors, while an aggressive thromboprophylasxis
with subcutaneous low molecular weight heparin (LMWH) should be
administered to cover high-risk situations.
However, the scenario could be different when considering solely
aPL carriers with an underlying autoimmune conditions: a 1998 study
on anti-CL positive patients with SLE reported an annual event rate of
3.8% [12]. Wahl and colleagues used a Markov decision analysis model
to evaluate the prophylactic role of LDA in aPL-positive SLE patients,
suggesting that it was effective in reducing the number of thrombotic
events. In particular, LDA induced a beneﬁt that outweighed the
treatment-associated risk of major bleeding [13]. Hence, there is
emerging evidence in support of LDA role in patients with underly-
ing autoimmune diseases. Systemic autoimmune conditions as SLE
and Rheumatoid Arthritis are now regarded as independent cardiovas-
cular risk factor, with systemic inﬂammation strongly contributing to
the accelerated atherosclerosis and overall cardiovascular burden. In
particular, thrombosis accounts for more than 1/3 of deaths related to
SLE, aPL status being the strongest predictor of thrombotic event.
Another group of patients at higher thrombosis risk that may ben-
eﬁt from LDA as primary prophylaxis is represented by aPL-positive
women with pregnancy morbidity not fulﬁlling the Sydney Criteria
for a formal diagnosis of APS. A retrospective study in aPL-positive
women who only experienced a fetal loss showed that LDA signiﬁ-
cantly reduced the incidence of vascular thrombosis after pregnancy:
the event incidence was 10% in those receiving LDA and 59% in the
untreated group [14]. In addition, an experts survey strongly suggests
therapy with LDA in women with a strong aPL positivity even during
the ﬁrst pregnancy owing to the high-risk of fetal loss.
Alternative therapeutic strategies have been recently proposed in
the management of aPL carriers: some studies have pointed out that
hydroxychloroquine (HCQ) may be useful to prevent the development
of thrombosis among lupus patients [15–17]. Certainly a better knowl-
edge of APS pathogenesis might help identifying new therapeutic tar-
gets. Nowadays there is little evidence of the beneﬁts of novel
treatment options, as rituximab or alternative antiplatelet drugs.
In conclusion, aPL carriers should be risk-stratiﬁed according to the
aPL status, the presence of cardiovascular risk factors, either inherited
or acquired. Modiﬁable risk factors should be promptly corrected;
estrogen-containing oral contraceptives should be avoided, LMWH
should be given in high-risk situations for venous thrombosis. The
best treatment strategy should be tailored according to the peculiar
risk proﬁle: primary thromboprophylaxis is not indicated in all unse-
lected asymptomatic aPL carriers. On the other hand, the coexistence
of an underlying systemic autoimmune disease, the concomitance of
non-modiﬁable procoagulant risk factors, a high-risk aPL proﬁle, a his-
tory of foetal loss should be counted as key-elements in favor of primary
thromboprophylaxis. It is important to avoid concomitant prescription
of LDA and anti-inﬂammatory drugs, as the latter can lead to actual re-
sistance to aspirin.
Research is currently aiming at identifying new aPL subsets, with
different pathogenetic potential: this would be helpful to further cat-
egorize patients.
3. Thromboprophylaxis in aPL carriers without previous thrombosis:
“con” view
Asymptomatic patients carrying only the laboratory criteria for
the APS [18] are at low risk of vascular complications and whetherers of antiphospholipid antibodies (APL) without previous thrombo-
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debate. To tackle this issue, the expected beneﬁt/risk of aspirin in the
prevention of thrombosis and the results of clinical studies in this set-
ting should be considered.3.1. Lessons from primary prevention trials with aspirin outside APS
The use of aspirin in six “primary” prevention trials enrolling ap-
proximately 58,000 persons who were at variable cardiovascular
risk has been reviewed [19]. If one compares the absolute beneﬁts
of aspirin prophylaxis in these trials, it becomes apparent that the
level of cardiovascular risk in the control population (i.e., those re-
ceiving placebo) is a major determinant of the absolute beneﬁt of
antiplatelet therapy. As a result, the ﬁrst step in deciding whether
to consider aspirin for primary prophylaxis is an assessment of the
annual risk for that individual of developing a cardiovascular event.
In other words, the balance between preventing vascular occlusion
and causing excess bleeding with aspirin depends critically on the ab-
solute thrombotic risk vs hemorrhagic risk of the patient. In individ-
uals who are at low risk for vascular occlusion (e.g., less than 1% per
year), a very small absolute beneﬁt is offset by exposure of a large
number of healthy subjects to undue bleeding complications. In con-
trast, in patients who are at high risk of cardiovascular or cerebrovas-
cular complications (e.g., >3% per year), the substantial absolute
beneﬁt of aspirin prophylaxis clearly outweighs the risk.3.2. Estimating the risk of thrombosis in asymptomatic carriers of
antiphospholipid antibodies (aPL)
Based on a limited number of studies [reviewed in 20], unselected
asymptomatic aPL carriers have a 0–2.8% annual thrombosis risk. In a
3-year prospective observational cohort study of 178 asymptomatic,
persistently aPL-positive individuals without systemic autoimmune
diseases, Giron-Gonzalez et al. reported no thromboses in partici-
pants receiving no prophylaxis (except during high-risk periods
such as surgeries) [2]. The Italian Registry of APS carried out a multi-
center, prospective cohort investigation of 360 unselected patients,
mostly with LA (>90%), prospectively observed for a median of
3.9 years (range 0.5 to 5) [10]. Overt LES or LES-like syndrome was di-
agnosed in 135 patients (37%). Thirty-four patients developed a
thrombotic complication, with a total incidence of 2.5% patient-
years. The incidence of thrombosis in 243 asymptomatic patients
(67%) was 0.95% per year. In patients with systemic autoimmune dis-
eases, the incidence of thrombosis was found to be slightly higher. A
recent prospective study of 258 aPL carriers (69% with an associated
systemic autoimmune diseases) followed for a mean of 35 months
(range 1–48) reported a ﬁrst thrombotic event in 14 subjects with
an annual incidence rate of 1.86%. In this study, thromboembolic
events were signiﬁcantly reduced only when antithrombotic prophy-
laxis was administered in high-risk situations and not continuously
[11].3.3. The role of associated thrombotic risk factors
The thrombosis risk in the general population riseswith the increas-
ing number of thrombosis risk factors and age.Well-established throm-
bosis risk factors such as hypertension or smoking can coexist in aPL-
positive individuals at the time of an event andmay even be responsible
for triggering acute thrombosis [9,21]. The results obtained in aspirin
trials that have recruited high-risk men and women demonstrate that
proper management of modiﬁable risk factors by current multifactorial
strategies can reduce the actual risk of experiencing a major vascular
event to a level at which the additional beneﬁt of aspirin does not clear-
ly outweigh the risk of major bleeding complications [19].Please cite this article as: Ceccarelli F, et al, Thromboprophylaxis in carri
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Primary thrombosis prophylaxis strategies in asymptomatic aPL-
positive individuals are poorly studied [20]. The Antiphospholipid
Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, ran-
domized, double-blind, placebo-controlled clinical trial in which
asymptomatic, persistently aPL-positive individuals were randomized
to receive a daily dose of 81 mg of aspirin or placebo [4]. In this study,
98 individuals were randomized to receive aspirin (n=48) or placebo
(n=50) (mean±SD followupperiod 2.30±0.95 years). The thrombo-
sis incidence rate was 2.75% patient-years for aspirin-treated subjects
and 0% patient-years for the placebo-treated subjects (hazard ratio
1.04, 95% CI 0.69–1.56) (P=0.83). In a parallel observational study,
the thrombosis incidence rates were 2.70% patient-years for aspirin-
treated subjects and 0% patient-years for those not treated with aspirin.
All but 1 patient with thrombosis in either study had concomitant
thrombosis risk factors and/or systemic autoimmune disease at the
time of thrombosis. These results suggest that asymptomatic, persis-
tently aPL-positive individuals do not beneﬁt from low-dose aspirin
for primary thrombosis prophylaxis, have a low overall annual inci-
dence rate of acute thrombosis, and develop vascular eventswhen addi-
tional thrombosis risk factors are present. There are some limitations of
this study, including the small sample size and insufﬁcient power
resulting from the rarity of aPL and the difﬁculty in identifying asymp-
tomatic aPL-positive patients. Despite these drawbacks, the APLASA
study is the ﬁrst randomized clinical trial of asymptomatic, persistently
aPL-positive individuals and its results are consistent with the bulk of
epidemiological and clinical data reviewed above.
Finally aspirin is not indicated in all asymptomatic patients with
conﬁrmed aPL positivity because: a) the estimated prevalence of
thrombosis in unselected cases is about 1% patient-years (range
0–2.8); b) this level of thrombotic risk is equivalent to that of major
bleeding associated with the use of aspirin and therefore the expected
beneﬁt does not outweigh the risk; c) these expectations have been
conﬁrmed by at least one randomized clinical trial, although with
methodological limits [9]. The management of modiﬁable thrombotic
risk factors can be an alternative and safer strategy, considering that
many vascular events occur in the presence of concomitant non-aPL
triggering conditions. Whether primary prophylaxis with aspirin
may be useful for some subsets of aPL patients at particularly high
thrombotic risk, such as those with overt SLE or with special patterns
of antibodies [22], remains to be established in appropriate clinical
studies.
4. Conclusion
In conclusion, the topic is quite controversial; in fact only few clin-
ical trials have evaluated the role of primary prophylaxis in this spe-
ciﬁc group of subjects. The contrasting results observed were
probably determined by the different study design, the small number
of cohort analyzed and the low incidence of events [2,4–6]. In partic-
ular, the APLASA study, the ﬁrst multicenter double-blind placebo-
controlled RCT in the area, compared a dose of 81 mg of aspirin
daily with placebo in asymptomatic aPL-positive individuals conclud-
ing that aspirin was not beneﬁcial in preventing thrombosis. This trial
showed some limitations, including a low incidence of events in both
groups, resulting perhaps by the exclusion of higher-risk patients
(those with obstetric APS) and inclusion of lower risk patients
(those with IgA aCL). Notably, all but one of the thrombotic events oc-
curred in patients with additional thrombotic risk factors, or autoim-
mune diseases. Another important limitation of APLASA study was
the small simple size included, due to recruitment difﬁculties, leaving
the study underpowered [4]. Prospective RCTs speciﬁcally designed
to evaluate the use of aspirin and other non-aspirin antithrombotic
therapies are required, considering larger cohorts, including also pa-
tients with high prothrombotic risk. In a commentary following theers of antiphospholipid antibodies (APL) without previous thrombo-
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for each treatment arm to achieve conclusive results. In clinical prac-
tice it is mandatory to eliminate modiﬁable prothrombotic risk fac-
tors, such as smoking or use of oral contraceptive. The irreversible
risk factors, such as hypertension and diabetes, should be treated
with speciﬁc and appropriate therapies. An aggressive prophylaxis
with subcutaneous LMWH should be administered to cover high-
risk situations, such as surgical procedures with prolonged immobili-
zation. A different evaluation should be addressed to aPL carriers af-
fected by a concomitant autoimmune diseases, such as SLE, that are
considered as an additional pro-thrombotic risk factor. Data today
available suggested that LDA in aPL-positive SLE patients could be ef-
fective to prevent thrombotic events, without signiﬁcant increase of
bleeding risk [13]. Moreover, in aPL-positive women with pregnancy
morbidity, LDA administration is suggested during the pregnancy, to
reduce the risk of fetal loss and after pregnancy to reduce the inci-
dence of vascular thrombosis after pregnancy [14]. Similarly, concom-
itant positivity for more than one test, particularly LA positivity, the
IgG isotype and medium-high titers confer a stronger risk of develop-
ing the clinical manifestations of the syndrome.
Recently the administration of HCQ is proposed as primary pro-
phylactic treatment, due to its anti-aggregant properties, particularly
in patients with SLE [15–17]. We can conclude that the primary
thromboprophylaxis is not indicated in all unselected asymptomatic
aPL carriers, and the best strategy in the treatment of aPL carriers
begin with the assessment of the peculiar risk proﬁle of the single
subject.
Take-home messages
• aPL are able to exert a pathogenetic role in APS.
• An additional trigger may be needed to develop a vascular event in
aPL carriers (second hit hypothesis).
• Few clinical trials, with no univocal results addressed the role of pri-
mary prophylaxis in aPL carriers.
• aPL carriers should be risk-stratiﬁed according to aPL status and
presence of cardiovascular risk factors (inherited or acquired).
• It is mandatory to eliminate modiﬁable prothrombotic risk factors,
and treat the irreversible risk factors with an aggressive prophylaxis
(subcutaneous LMWH) in high-risk situations.
• A concomitant autoimmune diseases, such as SLE, in aPL carriers
should be considered as an additional pro-thrombotic risk factor.
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